Tiagabine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2 mg, 4 mg, 12 mg, 16 mg
Reference Brands: Gabitril (USA/EU)
Category:
Neurology
Tiagabine Hydrochloride is available in Tablets
and strengths such as 2 mg, 4 mg, 12 mg, 16 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tiagabine Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tiagabine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tiagabine, marketed under the brand name Gabitril, is an anticonvulsant medication primarily used in the management of epilepsy. It is approved by the United States Food and Drug Administration (FDA) as an adjunctive therapy for the treatment of partial seizures in patients aged 12 years and older. Tiagabine is administered orally and is commonly prescribed alongside other antiepileptic drugs to enhance seizure control, although it may also be effective as monotherapy in selected cases.
Tiagabine works by selectively inhibiting the reuptake of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. By increasing GABA levels in the brain, tiagabine helps reduce abnormal neuronal activity associated with seizure disorders.
In addition to its approved indication for epilepsy, tiagabine has been used off-label in the management of certain anxiety disorders, including panic disorder, as well as for the treatment of insomnia under medical supervision. Its effectiveness in these conditions is attributed to its ability to stabilize neuronal signaling.
Tiagabine is manufactured in compliance with international quality standards and is available in multiple strengths to meet diverse therapeutic requirements. It remains a valuable option in neurology-focused treatment regimens for seizure management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing